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Serum Periostin: A Novel Biomarker
for Asthma Management
Hisako Matsumoto1
ABSTRACT
Chronic airway inflammation and remodeling are fundamental features of asthma. Even with adequate inhaled
corticosteroid (ICS) treatment, there are still patients who exhibit Th2eosinophilic inflammation and develop
airflow limitation, a functional consequence of airway remodeling. There are few biomarkers that are applicable
in the clinical setting that reflect refractory Th2eosinophilic inflammation and remodeling of the asthmatic air-
ways. Therefore, establishing such biomarkers is essential for managing patients who suffer from these condi-
tions.
This review addresses the importance of serum periostin measurements by describing observations made in
a KiHAC multicenter cohort with periostin used as a marker of pulmonary function decline and refractory Th2
eosinophilic inflammation in patients with asthma receiving long-term ICS treatment. Furthermore, serum pe-
riostin could be a companion diagnostic for targeted therapy against refractory Th2eosinophilic inflammation.
Finally, the distinct characteristics of serum periostin as compared to conventional biomarkers are addressed.
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INTRODUCTION
Airway inflammation and remodeling are fundamen-
tal features of asthma. To date, Th2eosinophilic in-
flammation has been considered to be the dominant
inflammatory pattern in asthma,1 although the in-
volvement of Th1,2 Th17,3,4 and neutrophilic inflam-
mation5,6 has been suggested based on recent evi-
dence. With the introduction of inhaled corticoster-
oids (ICS) treatment, which efficiently reduces the
production of Th2 and other cytokines by structural
and inflammatory cells and induces inflammatory cell
apoptosis, asthma in most patients can be success-
fully controlled. However, there still are patients with
uncontrolled severe asthma, comprising 5%-10% of the
total asthma population, and patients who develop air-
flow limitation, a functional consequence of airway re-
modeling,7,8 although these two populations often
overlap.
With the advent of several methods to obtain sam-
ples from the airways, including induced sputum9-16
and exhaled air,17,18 we and others identified various
biomarkers as being related to asthma pathophysiol-
ogy. However, there are few biomarkers that can be
easily accessed in clinical settings and may reflect re-
fractory Th2eosinophlic inflammation and remodel-
ing of the asthmatic airways.19 Serum periostin may
be one such biomarker to aid our understanding of
the pathobiophysiology of asthma.
In this review, the impact of serum periostin meas-
urements is addressed based on the axis of sustained
Th2eosinophilic inflammation and airway remodel-
ing in this ICS treatment era. Furthermore, the role
of serum periostin as a companion diagnostic for cur-
rently available and forthcoming biologics is pre-
sented.
CANDIDATE MARKERS FOR Th2EOSINO-
PHILIC INFLAMMATION AND REMODELING
IN THE ASTHMATIC AIRWAY
Among a number of Th2 cytokines and mediators, in-
terleukin (IL)-13 plays a pivotal role.20-22 This pleiot-
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ropic cytokine is derived from Th2 cells and innate
lymphoid cells23 and augments eosinophilic inflam-
mation, induces goblet cell hyperplasia and airway fi-
brosis, enhances agonist-induced contraction of the
airways, and changes intracellular Ca2+ homeostasis
in airway smooth muscle cells,24,25 which result in
airway remodeling. Several research groups have
successfully determined serum or sputum IL-13 lev-
els26-28 and reported its associations with asthma se-
verity. However, their rapid disappearance from in-
flammatory sites precludes the consistent detection
of IL-13 in serum; therefore, a “footprint” of IL-13 is
needed.
Refractory airway eosinophilia remains related to
airway remodeling in the ICS treatment era, although
this has only been reported for a limited population
with asthma.29 High sputum eosinophil counts in pa-
tients with asthma and fixed airflow limitations (post-
bronchodilator FEV1FVC of <0.7)30 and high ex-
haled nitric oxide (FeNO) levels in patients with se-
vere asthma and normal FEV1 (%FEV180%)31 are as-
sociated with accelerated declines in their pulmonary
function. Blood eosinophil counts, the simplest and
least expensive biomarker, do not reflect the develop-
ment of airflow limitation in the general asthma popu-
lation receiving ICS treatment, although blood
eosinophil counts are associated with airflow limita-
tion under steroid-naïve conditions.16,32,33
PERIOSTIN: A KEY MOLECULE LINKING
AIRWAY REMODELING AND Th2EOSINO-
PHILIC INFLAMMATION
Matricellular protein is a recent concept that was
coined for an extracellular matrix protein that causes
a vicious cycle of inflammation and remodeling. Pe-
riostin is one of these matricellular proteins and is
upregulated by IL-4 and IL-13 stimulation from airway
epithelial cells and other structural cells.34-36 Taka-
yama et al. were the first to demonstrate the deposi-
tion of periostin in the airway subepithelial layer in
patients with asthma.34 Subsequently, in airway epi-
thelial cells collected from patients with asthma, pe-
riostin was identified as one of the most upregulated
genes by microarray assay, with a 4.4-fold increase as
compared with healthy control subjects.35 This was
confirmed in a recent study from the same research
group by showing higher periostin gene expression
in sputum cells from patients with asthma compared
with sputum cells from healthy subjects.37
Airway epithelial cells from children with asthma
also had higher periostin expression (3.7-fold) than
cells from atopic non-asthmatic or healthy children,
which was not affected by ICS use.38 Furthermore,
periostin expression in airway epithelial cells was cor-
related with airway basement membrane thickness (r
= 0.56, p = 0.0002),36 and periostin could be detected
in serum samples of patients with asthma, which
largely reflected its level of production in the airways.
This was possibly because periostin is secreted ba-
sally by airway epithelial cells in response to IL-13
stimulation36 and thus may easily leak into the airway
capillaries.
Serum periostin has been identified as the single
best predictor of airway eosinophilia in patients with
severe asthma who remain symptomatic despite
maximal ICS treatment (>1000 μg daily equivalent to
fluticasone dipropionate; average %FEV1 60%, ACQ
score 2.7) in the Bronchoscopic Exploratory Re-
search Study of Biomarkers in Corticosteroid-
refractory Asthma (BOBCAT).39 The superiority of
serum periostin for predicting airway eosinophilia
was shown by logistic regression analysis that in-
cluded blood eosinophil counts, FeNO levels, and se-
rum IgE levels (n = 59).
Taken together, periostin may be a key molecule
that links remodeling and Th2eosinophilic inflam-
mation in the asthmatic airway. Therefore, its serum
level could be a reliable marker of airway remodeling
by reflecting refractory airway Th2eosinophilic in-
flammation in patients receiving ICS treatment.
To assess this hypothesis, we determined the se-
rum periostin levels in patients with asthma (n = 224;
average age: 62.3 years; 171 females) who were re-
cruited for the KiHAC multicenter study, a cohort to
identify serum markers and genetic factors associ-
ated with pulmonary function decline in patients with
asthma receiving long-term ICS treatment.40 In this
study, annual changes in FEV1 were assessed from at
least 1 year after initiating ICS treatment to the time
of enrolment or later (average of 16.2 measurements
for 8 years per individual). Serum periostin levels
were measured using an enzyme-linked immunosorb-
ent assay at Shino-test (Kanagawa, Japan), as previ-
ously described.41
Serum periostin levels of patients with asthma (av-
erage: 92.8 ngmL) were significantly higher than the
pooled serum periostin levels (average: 39.1 ngmL)
of 66 healthy subjects (average age: 60.7 years; 40
males). Serum periostin levels showed weak but posi-
tive correlations with blood eosinophil counts, serum
IgE and eosinophil cationic protein levels, ICS-
untreated periods, daily ICS maintenance doses at en-
rolment, and a history of admission due to asthma ex-
acerbation (p < 0.05). The comorbidity of chronic si-
nusitis as assessed by a self-completed questionnaire
was also a factor related to elevated serum periostin
levels in this population (Fig. 1).
Among several serum markers that included se-
rum eosinophil cationic protein, high sensitivity C re-
active protein, IL-6, and IL-17, serum periostin levels
were the sole biomarker for a greater annual decline
in FEV1. When using dichotomous data for high (95
ngmL; n = 85) and low (<95 ngmL) serum periostin
levels, which were determined by comparisons with
healthy subjects, high serum periostin was associated
with a decline in FEV1 of 30 mL・yr−1 or greater inde-
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Fig.　1　Associations between serum periostin levels and clinical indices, i.e. a) daily in-
haled corticosteroids (ICS) maintenance dose, b) a history of admission due to asthma 
exacerbation, and c) comorbidity of chronic sinusitis. Values shown are means + SE.
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Fig.　2　Distributions of patients who underwent post-
bronchodilator pulmonary function testing at study enrolment 
(n = 206) are shown based on patient age. Light blue bar in-
dicates patients with post-bronchodilator FEV1/FVC of ≥0.7 
(n = 136), yellow bar indicates patients with post-bronchodilator 
FEV1/FVC of <0.7 but with %predicted FEV1 of ≥80% (n = 
35), and orange bar indicates patients with post-bronchodilator 
FEV1/FVC of <0.7 and with %predicted FEV1 of <80% (n = 
35). The Berglund equation was used for predicted FEV1.
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pendently of the most intensive treatment step and
ex-smoking (10 pack-years). We also found that
one of the polymorphisms of the POSTN gene
(rs3829365) that encodes for periostin was associated
with higher serum periostin levels, suggesting that
besides IL-13, a master regulator of periostin, the ge-
netic background partly determines serum periostin
levels, although replication studies are necessary to
confirm this. Another POSTN gene polymorphism
(rs9603226) was associated with a decline in FEV1 of
30 mL・yr−1 by univariate analysis, particularly in
conjunction with high serum periostin levels.
In this KiHAC population, post-bronchodilator pul-
monary function results were obtained for 206 pa-
tients at enrolment when an average of eight years
had passed since their first pulmonary function tests.
A total of 70 (34%) fulfilled the criteria of fixed airflow
limitation (post-bronchodilator FEV1FVC of <0.7),
and for patients aged65 years (n = 103), 47% showed
fixed airflow limitation; a substantial number of eld-
erly patients with asthma (10 pack-years) had fixed
airflow limitations (Fig. 2). In a cross-sectional analy-
sis, high serum periostin was a factor associated with
lower post-bronchodilator FEV1FVC at enrolment
for patients whose initial FEV1FVC (pre-broncho-
dilator) was 0.7 and independent of the most inten-
sive treatment step and high blood neutrophil counts
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Table　1　Multivariate analysis for the relationships between 
post-bronchodilator FEV1/FVC at enrolment and clinical indices 
in patients with asthma with initial FEV1/FVC of ≥0.7 (n = 142)
Correlation
coefficients
p value
Treatment Step†, 5 vs 2-4 -0.16 0.036
Smoking history, ex‡ vs never -0.03 ns
Serum periostin, high vs low§ -0.19 0.016
Blood neutrophil counts -0.17 0.029
Adjusted by sex, height, age at enrolment, and observation peri-
od from the fi rst measurement.
†According to the Global Initiative for Asthma 2010 guideline.
‡≤10 pack-years.
§high: ≥95 ng/mL, low: <95 ng/mL.
(Table 1).
WHICH PATIENTS SHOULD BE MEASURED
FOR SERUM PERIOSTIN?
The aforementioned findings confirmed an associa-
tion between periostin and airway remodeling, al-
though these findings may be insufficient for extrapo-
lation to clinical settings. We then translated our find-
ings of serum periostin levels to patient-based infor-
mation, by taking into account the time-axis.
Although Th2eosinophilic inflammation is a domi-
nant inflammatory pattern with asthma, complex in-
teractions between genetic predisposition, environ-
mental factors, and aging render asthma as a hetero-
geneous disease with varying phenotypes. To date,
several attempts have been made to categorize the
complex population of asthmatics into distinct sub-
groups using cluster analysis, an unbiased analy-
sis.42-45 These studies have commonly identified be-
nign asthma with little evidence of active disease,
early-onset atopic asthma, and obese non-eosinophilic
asthma.
Haldar et al. identified two additional clusters in re-
fractory asthma: early-onset symptom-predominant
asthma and late-onset eosinophilic asthma with few
symptoms.42 The latter phenotype of late-onset
eosinophilic asthma with few symptoms was also re-
ported in a recent analysis of patients with adult-onset
asthma.45 We also identified four distinct clusters in
the KiHAC population.46 Among the four clusters
identified, one cluster (n = 73) was characterized
by late-onset, eosinophilic, and moderate decline in
FEV1. Another cluster (n = 21) was characterized by
mixed type inflammation (eosinophilic and neutro-
philic) with the lowest FEV1, highest decline in FEV1,
and lowest asthma control among the four clusters.
Serum periostin levels were the highest in the late-
onset, eosinophilic cluster (n = 73), followed by the
cluster with mixed type inflammation (n = 21). Most
of the patients with a rapid FEV1 decline, defined as a
decline of 30 mL・yr−1, were included in these two
clusters. Thus, we propose that serum periostin
should be measured for individuals who are charac-
terized by these clusters. Of note, the late-onset,
eosinophilic cluster in our population may overlap
with the emerging cluster that was characterized by
late-onset eosinophilic asthma with few symptoms42,45
for which serum periostin measurements may lead to
better management of patients who are at risk of
under-treatment with regard to pulmonary function
when symptom-based strategies are implemented.
Because serum periostin may reflect latent airway
inflammation, it is conceivable that serum periostin
levels may predict the instability of asthma after ICS
doses are tapered. In a pilot study, Kato et al. showed
that initial serum periostin levels were higher in pa-
tients who were apparently well-controlled but
showed deterioration in asthma at 12 weeks after the
ICS dose was tapered compared with those who re-
mained stable.47
SERUM PERIOSTIN AS A COMPANION DI-
AGNOSTIC FOR BIOLOGICS
Several new biologics,48 including anti-IL-1349 and
anti-IL-5 antibodies,50 will be available in the very
near future. Patients with uncontrolled asthma receiv-
ing ICS treatment are expected to benefit from these
biologics; however, not all patients may respond to
these costly biologics. Therefore, identifying re-
sponders to these biologics using good predictors
(i.e., companion diagnostics) is necessary to effi-
ciently apply these biologics.
In a phase IIb study of lebrikizumab (n = 219), an
anti-IL-13 antibody, Corren et al. demonstrated that
serum periostin was a good predictor of the response
to lebrikizumab in patients with unstable asthma de-
spite ICS therapy.49 The high serum periostin group
(n = 110) showed an 8.2% increase in FEV1 in re-
sponse to lebrikizumab compared with the placebo
group, whereas there was a 1.6% increase in FEV1 for
the serum low periostin group (n = 101).
Similarly, the EXTRA omalizumab study (total n =
850) showed that serum periostin could be a predic-
tive marker of responses to omalizumab, anti-IgE an-
tibody, in patients with severe asthma, in addition to
blood eosinophil counts and FeNO levels. When pa-
tients had high serum periostin levels (n = 255), the
rate of severe exacerbations declined by 30% when
treated with omalizumab, whereas the decrease with
omalizumab treatment was only 3% in the low serum
periostin group (n = 279).51
Periostin is overexpressed in the nasal tissues of
patients with eosinophilic chronic rhinosinusitis
(ECRS).52 We also determined serum periostin levels
in patients with ECRS concomitant with severe
asthma who were subsequently treated with omalizu-
mab. These patients showed significant improve-
ments in sinus CT scores as well as total and rhi-
nological symptom scores in SNOT-20, scores for na-
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Fig.　3　Initial response levels of exhaled nitric oxide (FeNO) and serum periostin to 
inhaled corticosteroids treatment (n = 37). Values shown are means ± SE.
*By paired t test, vs baseline.
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Fig.　4　Schematic diagram of Th2/eosinophilic (Eo) airway 
pathobiology that could be evaluated by exhaled nitric oxide 
levels (FeNO) and serum periostin levels.
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sal blockage and dysosmia after a 16-week treatment
with omalizumab.53 Although there were very few pa-
tients, the changes in sinus CT scores were strongly
correlated to baseline serum periostin levels (r =
−0.92; p = 0.029; n = 5), suggesting that serum pe-
riostin level may be a predictor of the responses to
omalizumab treatment for ECRS.
Finally, in a recent study of lebrikizumab that was
given to steroid-naïve patients with asthma (n = 210),
its effect on FEV1 was insufficient irrespective of se-
rum periostin levels.54 Therefore, the effects of an
anti-IL-13 antibody and the role of serum periostin as
a companion diagnostic should be carefully inter-
preted for steroid-naïve patients, although it may be
pronounced when applied to patients who are symp-
tomatic on ICS treatment and are thus considered
relatively ICS insensitive. The possible associations
between periostin and ICS insensitivity are discussed
below.
PERIOSTIN RESPONSES TO MEDICATIONS
Th2eosinophilic inflammation is not always steroid
sensitive, which is often referred to as refractory in-
flammation in patients with severe asthma. This is
also true for periostin production. From in vitro stud-
ies, steroid treatment efficiently decreases IL-4IL-13-
induced periostin production by airway epithelial
cells35 and fibroblasts34 but does not inhibit TGF-β-
induced periostin production by fibroblasts or IL-4
IL-13-induced periostin production by microvascular
endothelial cells.55 Serum periostin levels were sig-
nificantly decreased by an average of 17.2% (placebo
corrected) from the baseline levels after 14 days of
treatment with oral prednisolone (0.5 mgkgday) in
the BIOAIR study (n = 118).56 A 12-week treatment
with lebrikizumab also decreased serum periostin
levels by 9.7% (placebo corrected) in all patients and
by 14.4% in the high periostin group.57 In steroid-
naïve patients with asthma, introduction of ICS
(equivalent to fluticasone propionate 400 μg daily)
significantly decreased serum periostin levels at 24
weeks but only by 5.4% from the baseline (n = 37;
mean age 55 years, 10 males) (Fig. 3) (Otsuka K,
Takeda T, et al. unpublished data).
Potent systemic anti-inflammatory treatments may
decrease serum periostin levels, whereas the effects
of ICS on serum periostin levels appear to be mini-
mal. This was in contrast to the changes in FeNO lev-
els that significantly decreased by 27.4% at 12 weeks
from the baseline levels in the same steroid naïve pa-
tients (n = 37) (Fig. 4). Further studies will be needed
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to confirm these preliminary findings, although
FeNO levels may reflect relatively acute inflammation
in the Th2eosinophilic airways, whereas serum pe-
riostin levels may reflect chronic or latent inflamma-
tion and remodeling of the asthmatic airways with
ICS treatment (Fig. 4).
Blood eosinophil counts, FeNO, and serum pe-
riostin levels may be compensatory or composite
markers of Th2eosinophilic inflammation, although
serum periostin levels may be distinct from other
conventional biomarkers by integrating the informa-
tion for chronic inflammation and remodeling in the
Th2eosinophilic airway. Furthermore, as different
from FeNO and blood eosinophil counts, serum pe-
riostin levels are stable and with little variability,
which is required for a reliable biomarker. In the
phase IIb study of lebrikizumab, the average coeffi-
cients of variation (CV) for FeNO, blood eosinophil
counts, and serum periostin that were assessed at 1
week apart during the run-in period were 19.8%,
21.3%, and 5.0%, respectively.49 Consistently, in the
BOBCAT study, CV for FeNO and serum periostin
that were assessed at 2-3 weeks apart were 8.2% and
2.2%, respectively.39
CONCLUSION
Although more studies are needed to validate and es-
tablish its utility in asthma management, serum pe-
riostin is a novel biomarker in asthma that integrates
the information on refractory Th2eosinophilic in-
flammation and remodeling of the airways and could
be a companion diagnostic for Th2-targeted therapy.
This distinct characteristic of serum periostin may
provide a platform for elucidating the mechanisms
underlying persistent airway Th2eosinophilic inflam-
mation in asthma during this ICS treatment era.58
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